지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.1
- 수록면
- 819 - 828 (10page)
이용수
이 논문의 연구 히스토리 (2)
2021
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells : Combined therapy with chk1 inhibitor and Rucaparib in ovarian cancer
조혜연
의학과
2021.01
학위논문
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
조혜연
,
김용범
,
박욱하
외 1명
Cancer Research and Treatment
2021.01
학술저널
- 이 논문의 후속연구가 궁금하신가요?
- 연관 학술논문 또는 학술발표를 통해 보다 발전된 연구결과를 확인하실 수 있습니다.
- 이 논문의 연구 히스토리 확인하기
초록· 키워드
오류제보하기
Purpose This study aimed to evaluate anticancer effects of combination treatment with poly(ADP-ribose) polymerase (PARP) and checkpoint kinase 1 (Chk1) inhibitors in BRCA wild-type ovarian cancer. PARP inhibitors can function as DNA-damaging agents in BRCA wild-type cancer, even if clinical activity is limited. Most epithelial ovarian cancers are characterized by a TP53 mutation causing dysfunction at the G1/S checkpoint, which makes tumor cells highly dependent on Chk1-mediated G/M phase cell-cycle arrest for DNA repair.Materials and Methods We investigated the anticancer effects of combination treatment with prexasertib (LY2606368), a selective ATP competitive small molecule inhibitor of Chk1 and Chk2, and rucaparib, a PARP inhibitor, in BRCA wild-type ovarian cancer cell lines (OVCAR3 and SKOV3).Results We found that combined treatment significantly decreased cell viability in all cell lines and induced greater DNA damage and apoptosis than in the control and/or using monotherapies. Moreover, we found that prexasertib significantly inhibited homologous recombination?mediated DNA repair and thus showed a marked anticancer effect in combination treatment with rucaparib. The anticancer mechanism of prexasertib and rucaparib was considered to be caused by an impaired G2/M checkpoint due to prexasertib treatment, which forced mitotic catastrophe in the presence of rucaparib.Conclusion Our results suggest a novel effective therapeutic strategy for BRCA wild-type epithelial ovarian cancer using a combination of Chk1 and PARP inhibitors.
목차
등록된 정보가 없습니다.
참고문헌 (1)
참고문헌 신청
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
난소암 표적치료 및 면역치료
대한의사협회지
2016 .01
-
Interleukin-34 cancels anti-tumor immunity by PARP inhibitor
Journal of Gynecologic Oncology
2023 .05
-
Adherence of PARP inhibitor for frontline maintenance therapy in primary epithelial ovarian cancer: a cross-sectional survey
Journal of Gynecologic Oncology
2024 .01
-
Comparison of Targeted Next-Generation and Sanger Sequencing for the BRCA1 and BRCA2 Mutation Screening
Annals of Laboratory Medicine
2016 .01
-
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations
Journal of Breast Cancer
2018 .01
-
Cost-effective BRCA Testing in Advanced Ovarian Cancer
Annals of Laboratory Medicine
2023 .01
-
BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea
Journal of Gynecologic Oncology
2018 .01
-
Overview of fuzuloparib in the treatment of ovarian cancer: background and future perspective
Journal of Gynecologic Oncology
2022 .11
-
Methylation Status and Expression of BRCA2 in Epithelial Ovarian Cancers in Indonesia
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Comparison of Clinical Outcomes of BRCA1/2 Pathologic Mutation, Variants of Unknown Significance, or Wild Type Epithelial Ovarian Cancer Patients
Cancer Research and Treatment
2017 .01
-
Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
Journal of Gynecologic Oncology
2023 .03
-
Novel Germline Mutation of BRCA1 Gene in a 56-Year-Old Woman with Breast Cancer, Ovarian Cancer, and Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2015 .01
-
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer
Obstetrics & Gynecology Science
2020 .01
-
BRCA1/BRCA2 Pathogenic Variant Breast Cancer: Treatment and Prevention Strategies
Annals of Laboratory Medicine
2020 .01
-
BRCA1/2 mutation status in patients with metachronous breast and ovarian malignancies: clues towards the implementation of genetic counseling
Journal of Gynecologic Oncology
2020 .01
-
BRCA1-mutated ovarian cancer with skin metastasis: a case report
Obstetrics & Gynecology Science
2017 .01
-
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
Journal of Gynecologic Oncology
2024 .03
-
Uptake Rate of Risk-Reducing Salpingo-Oophorectomy and Surgical Outcomes of Female Germline BRCA1/2 Mutation Carriers: A Retrospective Cohort Study
Yonsei Medical Journal
2021 .12
-
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Journal of Korean Medical Science
2021 .10
-
Prevalence and oncologic outcomes of BRCA1/2 mutation and variant of unknown significance in epithelial ovarian carcinoma patients in Korea
Obstetrics & Gynecology Science
2019 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0